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ORIGINAL RESEARCH

Microarray-Based Cancer Prediction Using Soft
Computing Approach
Xiaosheng Wang 1 and Osamu Gotoh 1,2
1

Department of Intelligence Science and Technology, Graduate School of Informatics, Kyoto University,
Kyoto 606–8501, Japan. 2National Institute of Advanced Industrial Science and Technology,
Computational Biology Research Center, Tokyo 135-0064, Japan.
Abstract: One of the difÞculties in using gene expression proÞles to predict cancer is how to effectively select a few
informative genes to construct accurate prediction models from thousands or ten thousands of genes. We screen highly
discriminative genes and gene pairs to create simple prediction models involved in single genes or gene pairs on the basis
of soft computing approach and rough set theory. Accurate cancerous prediction is obtained when we apply the simple
prediction models for four cancerous gene expression datasets: CNS tumor, colon tumor, lung cancer and DLBCL. Some
genes closely correlated with the pathogenesis of speciÞc or general cancers are identiÞed. In contrast with other models,
our models are simple, effective and robust. Meanwhile, our models are interpretable for they are based on decision rules.
Our results demonstrate that very simple models may perform well on cancerous molecular prediction and important gene
markers of cancer can be detected if the gene selection approach is chosen reasonably.
Keywords: gene expression proÞles, cancer prediction, soft computing, rough set theory, feature selection, decision rules

Introduction
Conventional tumor diagnostic methods based on the morphological appearance of tumors are not
always effective as misdiagnoses often occur. On the other hand, a wide variety of studies have revealed
cancer to be a disease involving dynamic changes in the genome. Therefore, using molecular markers
of cancers might be an alternative approach to the diagnosis of tumors. The rapid advances in gene
expression microarray technology that enable simultaneously measuring the expression levels for tens
of thousands of genes in a single experiment, make the detection of cancerous molecular markers
possible.1 Since the pioneering work of Golub et al in applying gene expression monitoring by DNA
microarray to cancer classiÞcation,2 many investigations of using microarray technology to build cancer
diagnosis, prognosis or prediction classiÞers have been conducted. In general, the major difÞculty in
this topic is how to effectively identify the genes pertaining to the pathogenesis of speciÞc cancers from
the extremely high-dimensionality gene expression data, which often contain a large amount of noise
caused by irrelevant genes. On the other hand, compared with the measured quantities of gene expression
levels in experiments, the numbers of samples are severely limited. That often inßuences prediction
accuracy. In this extreme of very few observations on very many features, it is natural and perhaps
essential to investigate feature selection and regularization methods.3 Feature selection, i.e. gene Þltering,
is particularly crucial for microarray-based cancer prediction since the number of irrelevant genes for
prediction may be huge, and as long as feature selection is performed reasonably, accurate prediction
is achieved with even the simplest of predictive models.4
Various methods of building cancer predictors have been proposed such as Clustering, SVMs (Support
Vector Machines), k-NNs (k-Nearest Neighbours), ANNs (ArtiÞcial Neural Networks), GAs (Genetic
Algorithms), Naive Bayes (NB), DTs (Decision Trees), RSs (Rough Sets), EPs (Emerging Patterns),
et al. In this article, we explore the use of rule-based pipelines to construct cancer predictors as the
rule-based methods are more likely to be accepted by biologists and clinicians for they are easily understood. This kind of approaches like DTs,5 RSs,6 EPs7 etc. have been commonly utilized to produce
cancer predictors by many investigators.7–14 In addition, we attempt to employ one or two genes to
conduct cancer prediction. The same problem also has been addressed by some investigators.15,16
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Our method is based on rough set theory,
originally proposed by Pawlak in the early 1980s,6
which can be applied for analysis of both precise
and imprecise data.17 In,8–11 rough set theory is
applied for cancer classiÞcation and prediction.
A majority of these studies conduct feature
selection by the attribute reduction approach, one
core idea of rough set theory. However, to our
knowledge, rough sets attribute reductions are
computationally expensive, and the resultant
reducts maybe are not unique. Moreover, the
reducts cannot ensure high prediction performance
because there maybe exists redundancy between
the attributes in one reduct.18 To avoid expensive
cost in computing attribute reductions, we select
the features (genes) with perfect attribute depended
degree, a concept from rough set theory, and then
create rule classiÞers by the chosen genes instead
of running attribute reductions. As it is very
difÞcult to Þnd the single genes or gene pairs with
perfect attribute depended degree in terms of the
canonical deÞnition, we extend the concept of
attribute depended degree to the more ßexible soft
computing framework. Using the extended deÞnition of attribute depended degree, we can detect
some single genes or gene pairs with indeed strong
class discriminatory power while they will be
ignored if the conventional attribute depended
degree standard is employed. Consequently,
although the rules derived from the detected genes
or gene pairs might not be absolutely true, they
are comparatively reliable and able to perform
effective prediction.
We apply our algorithm to the four noted gene
expression datasets: central nervous system
(CNS) tumor, colon tumor, lung cancer, and
diffuse large B-cell lymphoma (DLBCL). They
are available from the Kent Ridge Bio-medical
Data Set Repository (http://datam.i2r.a-star.edu.
sg/datasets/krbd/). We validate the efÞcacy of our
method by leave-one-out cross-validation
(LOOCV), and compare our results with other
already published research outcomes. Furthermore,
we examine and analyze the biological relevance
of the selected genes.

Results
CNS tumor dataset
In the dataset, we Þrst try to Þnd the single genes
with high class discriminative power. When α is
set to 0.9 or 0.85, there is no gene with α depended
124

degree equal to 1 occurring in all the 60 training
sets; when α is set to 0.8, gene U28963_at occurs
in 59 out of the 60 training sets; when α is set to
0.75 and 0.7, there are two and six genes occurring
in all the 60 training sets, respectively. In every
training set, each of the six genes results to two
decision rules, which are used to predict the test
sample. The Þnal prediction estimate is the average
of 60 test results. Table 1 shows the prediction
results by the six genes. Subsequently, we attempt
to seek for the gene pairs with strong class discriminative ability. When α is set to 0.9, no gene
pair is detected; when α is set to 0.85, only one
gene pair is detected; when α is reduced to 0.8,
eleven gene pairs are found. In general, each gene
pair produces four decision rules. Then we apply
the four decision rules to classify the test sample
and the average of 60 test results is the prediction
estimate of the gene pair. Table 2 shows the prediction results by the eleven gene pairs.
Here we denote the expression level of gene G
by g(G). When the Þrst sample is left out as the
test set, and the remaining samples set is trained
by the learning algorithm, the selected gene
U28963_at will give rise to two decision rules:
• If g(U28963_at) # 431, then Class 1;
• If g(U28963_at) .431, then Class 0.
The two rules have 81% and 84% conÞdence,
respectively. One can use the two rules to classify
the test set. When another sample instead of the
Þrst one is left out, gene U28963_at will result to
two similar decision rules:
• If g(U28963_at) # x, then Class 1;
• If g(U28963_at) . x, then Class 0.
x equals to 431 or is close to it. Anyway, the rules
imply that if gene U28963_at is up-regulated in
Table 1. 6 genes with high prediction accuracy in the
CNS tumor dataset.
Probe ID

Correctly-classiÞed
sample number
(accuracy)

α

U28963_at

47 (78%)

0.75

X99050_rna1_at

45 (75%)

0.75

D83542_at

46 (77%)

0.7

S71824_at

50 (83%)

0.7

U37673_at

40 (67%)

0.7

D86974_at

45 (75%)

0.7
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Table 2. 11 gene pairs with high prediction accuracy in the CNS tumor dataset.
1st – 2nd Probe ID

Correctly-classiÞed
sample number (accuracy)

α

D83542_at–S71824_at

54 (90%)

0.85

D31763_at–U08998_at

54 (90%)

0.8

D83542_at–X99050_rna1_at

49 (82%)

0.8

D83542_at–D86974_at

52 (87%)

0.8

L33243_at–U36448_at

52 (87%)

0.8

M73547_at–U74324_at

51 (85%)

0.8

M96739_at–U36448_at

54 (90%)

0.8

S71824_at–D86974_at

51 (85%)

0.8

U37143_at–D43682_s_at

48 (80%)

0.8

U79277_at–D43682_s_at

47 (78%)

0.8

X99050_rna1_at–D86974_at

49 (82%)

0.8

one CNS tumor patient, the patient will be more
inclined to succumb to the disease. The other
chosen genes give rise to similar form of rules.
Likewise, when the first sample is left out
for test while the remaining samples are retained
for training, the selected gene pair D83542_
at—S71824_at will generate four decision rules:
• if g(D83542_at) # 280.5 and g(S71824_at) #
434, then Class 1;
• if g(D83542_at) # 280.5 and g(S71824_at) .
434, then Class 1;
• if g(D83542_at) . 280.5 and g(S71824_at) #
434, then Class 1;
• if g(D83542_at) . 280.5 and g(S71824_at) .
434, then Class 0.
The four rules possess 100%, 100%, 89% and
88% conÞdence, respectively. They can be simpliÞed into equivalent three rules:
• if g(D83542_at) # 280.5 , then Class 1;
• if g(S71824_at) # 434, then Class 1;
• if g(D83542_at) . 280.5 and g(S71824_at) .
434, then Class 0.
The three rules have 100%, 92% and 88% conÞdence, respectively. One can employ the four or
alternative three rules to classify the test set. When
another sample instead of the Þrst one is left out,
gene pair D83542_at—S71824_at will generate
four similar decision rules. These rules indicate
that if both D83542_at and S71824_at are highly
expressed in one CNS tumor patient, then the patient
will be very likely to succumb to the disease.
Cancer Informatics 2009:7

Similar rules can be derived by the other chosen
gene pairs.

Colon tumor dataset
Using the same learning algorithm for the dataset,
we screen the genes and gene pairs with comparatively high prediction performance. The results are
presented in Table 3 and Table 4. As before, decision rules can be induced by the selected genes or
gene pairs.

Lung cancer dataset
In the dataset, when α is set to 0.8, no any gene is
detected; when α equals to 0.75, eight genes are
detected; when α is reduced to 0.7, no more genes
are found. To make the decision rules induced by
gene more reliable, we exclude the genes with
missing values. When α is set to 0.9, 0.85 or 0.8,
no any gene pair is found; when α is reduced to
0.75, eight gene pairs are detected. The results are
presented in Table 5 and Table 6.

DLBCL dataset
In the dataset, when α is set to 0.7, there are four
genes selected; when α increases to 0.75, no any
gene is found. With respect to gene pairs, when α
is set to 0.9 or 0.85, no any gene pair is found;
when α decreases to 0.8, there are 22 gene pairs
chosen. The results are presented in Table 7 and
Table 8. Table 8 shows only 20 out of the 22 gene
pairs. The other two gene pairs are omitted because
of their overly low prediction accuracy.
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Table 3. 21 genes with high prediction accuracy in the
colon tumor dataset.
GenBank
accession
no.

Correctly-classiÞed
sample number
(accuracy)

α

M63391

52 (84%)

0.8

M76378

50 (81%)

0.8

J02854

50 (81%)

0.8

M26383

52 (84%)

0.8

M76378

50 (81%)

0.75

T60155

48 (77%)

0.75

M22382

50 (81%)

0.75

X12671

49 (79%)

0.75

M76378

50 (81%)

0.75

T96873

47 (76%)

0.75

X86693

47 (76%)

0.75

J05032

50 (81%)

0.75

U25138

48 (77%)

0.75

T60778

47 (76%)

0.75

M91463

48 (77%)

0.75

R87126

51 (82%)

0.7

T51571

46 (74%)

0.7

T92451

48 (77%)

0.7

U09564

48 (77%)

0.7

R97912

45 (73%)

0.7

L41559

45 (73%)

0.7

Comparison of Prediction
Performance
CNS tumor dataset

The dataset is dataset C mentioned in19 that is used
to analyze the outcome of the treatment for central
nervous system embryonal tumor patients. In this
dataset, we gain the 83% and 90% best prediction
accuracy using one and two genes respectively.
In,19 Pomeroy et al use a k-NNs algorithm to construct outcome predictor based on gene expression.
The reported statistically signiÞcant gene size for
k-NN models ranges from 2 to 21 genes, with the
best prediction made by an 8-gene model that made
13/60 classiÞcation errors. Several other prediction
algorithms including weighted voting, SVMs, and
IBM SPLASH are also tested in.19 In,20 Zhang et
al propose a hybrid approach, which combines
discernibility matrix, the Þlter strategy and the
wrapper method to select gene sets. Then they
126

adopt the classifiers C4.5 and NaiveBayes to
evaluate the prediction performance of the gene
sets. Their prediction accuracy by LOOCV is 75%
for C4.5 using 20 genes and 86.67% for NaiveBayes using 29 genes. In,12 Tan et al use decision
trees (Single C4.5, Bagging C4.5, AdaBoost C4.5)
to perform prediction tasks on cancerous microarray data including the CNS tumor dataset. They
Þrst employ Fayyad and Irani’s21 discretization
method to screen 74 genes for the actual learning
process. Their highest prediction accuracy is 88%
by tenfold cross-validation. The comparison of our
methods with the others is summarized in Table 9.
The table shows that our results are better than
almost all the other compared results from previous
studies.
Colon tumor dataset
The dataset is Þrst studied by Alon et al.22 They
propose two-way clustering approach that classify
genes into functional groups and classify tissues
based on their gene expression similarity. Since their
original work, the dataset has been frequently
investigated by other investigators. In this dataset,
we reach the 84% and 90% highest prediction
accuracy using one and two genes respectively.
Table 10 compares the prediction results of our work
with some other studies. The table demonstrates that
whereas we use the least genes, our prediction
accuracy is superior to or matches the others.

Lung cancer dataset
In this dataset, we obtain the 85% and 82% highest
prediction accuracy using one and two genes
respectively. With respect to this dataset, we only
Þnd that Zhang et al report their study results20
apart from the original paper.23 Table 11 presents
the comparison between our method and that
provided in. 20 Although their best prediction
accuracy by the HFW feature selection approach
is a little higher than ours, the numbers of the genes
used by them far exceed ours. As for the other
feature selection approaches including FCBF, CFSSF and ReliefF, the prediction performance caused
by them is inferior to ours.

DLBCL dataset
In this dataset, we achieve the 78% and 90% best
prediction accuracy using one and two genes
respectively. Table 12 gives the comparison
Cancer Informatics 2009:7

Microarray-based cancer prediction using soft computing approach

Table 4. 16 gene pairs with high prediction accuracy in the colon tumor-dataset.
1st – 2nd GenBank
accession no.

Correctly-classiÞed sample
number (accuracy)

α

T51571–J02854

56 (90%)

0.9

J02854–L41559

56 (90%)

0.9

M76378–M63391

52 (84%)

0.85

M63391–M76378

52 (84%)

0.85

M63391–Z49269

45 (73%)

0.85

M63391–X86693

53 (85%)

0.85

Z50753–H40095

55 (89%)

0.85

R87126–H81068

55 (89%)

0.85

X12671–J02854

56 (90%)

0.85

X12671–M26383

54 (87%)

0.85

M76378–M26383

55 (89%)

0.85

H40095–M36634

54 (87%)

0.85

R97912–J02854

55 (89%)

0.85

R97912–M26383

54 (87%)

0.85

R06601–X63629

54 (87%)

0.85

M36634–H08393

56 (90%)

0.85

between our method and that provided in20 and24
Obviously, our results dominate the others.

Analysis of Biological Relevance
CNS tumor dataset
In this dataset, we identify six genes with
comparatively high prediction performance
individually. The six genes are U28963_at,
X99050_rna1_at, D83542_at, S71824_at, U37673_
at, and D86974_at. According to the decision rules
Table 5. 8 genes with high prediction accuracy in the
lung cancer dataset.
Unigene ID

505266a
Hs.95243
Hs.25882
Hs.275198
36491a
Hs.170225
Hs.17258
Hs.11556
a

Correctly-classiÞed
sample number
(accuracy)
32 (82%)
32 (82%)
32 (82%)
32 (82%)
32 (82%)
33 (85%)
29 (74%)
31 (79%)

The Unigene ID is not available.

Cancer Informatics 2009:7

α

0.75
0.75
0.75
0.75
0.75
0.75
0.75
0.75

induced by the genes, we suspect that they are all
over-expressed in the patients who succumb to
their disease. As expected, three out of the six
genes are picked as the markers of survival by
Pomeroy et al.19 The three genes are referred to as
GPS2 (U28963_at), beta-NAP (U37673_at) and
KIAA0220 gene (D86974_at) respectively. Moreover, beta-NAP and KIAA0220 gene are the
members of the 8-gene model by which k-NN
makes optimal prediction. In addition, three genes
named Human polyposis locus (DP1 gene), NSCL1
and VLCAD which compose the gene pairs with
strong prediction power are also identified as
markers of survival by Pomeroy et al.19
GPS2 encodes a protein involved in G proteinmitogen-activated protein kinase (MAPK) signaling cascades. The function of this gene may be
signal repression. Zhang et al indicate that GPS2
interacts with another protein RFX4_v3 to
modulate transactivation of genes involved in brain
morphogenesis.25 Therefore, the dysregulation
of GPS2 may be closely correlated with the
pathogenesis of CNS tumor. Beta-NAP, a cerebellar
degeneration antigen, is a neuron-speciÞc vesicle
coat protein.26 NSCL1 is the gene expressed
predominantly in the developing nervous system.27
Our rules indicate that if the gene is over-expressed,
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Table 6. 8 gene pairs with high prediction accuracy in the lung cancer dataset.
1st – 2nd Unigene ID

Correctly-classiÞed sample
number (accuracy)

α

Hs.169611–Hs.285701

31 (79%)

0.75

Hs.285701–Hs.132415

29 (74%)

0.75

Hs.285701–Hs.57655

30 (77%)

0.75

Hs.57655–Hs.8595

31 (79%)

0.75

Hs.184542–Hs.58323

31 (79%)

0.75

Hs.262823–Hs.8595

31 (79%)

0.75

Hs.262480–Hs.772

32 (82%)

0.75

31 (79%)

0.75

Hs.112193–505266

a

the patients will be more likely to succumb to the
CNS tumor. It coincides with the observation
reported in.27
Colon tumor dataset
In this dataset, we identify 21 genes which can
result to relatively efÞcient prediction individually.
Some of these genes have been proved to tightly
link with the pathogenesis of colon tumor or other
tumors. Desmin is identiÞed as one of three known
hub cancer genes in colon cancer-speciÞc gene
network.28 Our rules indicate that the gene is downregulated in colon tumor samples. The same
conclusion is provided in.29 The gene CRP encodes
a member of the cysteine-rich protein (CSRP)
family. This gene family includes a group of LIM
domain proteins, which may be involved in
regulatory processes important for development
and cellular differentiation. The LIM/double zincÞnger motif found in this gene product occurs in
proteins with critical functions in gene regulation,
cell growth, and somatic differentiation. This gene
has been reported to be associated with several
cancers.30–32 MONAP belongs to angiogenesisrelated genes. Its overexpression is associated with
Table 7. 4 genes with high prediction accuracy in the
DLBCL dataset.
Probe ID

U70663_at
M17863_s_at
U48865_s_at
U90543_at

128

Correctly-classiÞed
sample number
(accuracy)

α

44 (76%)
44 (76%)
43 (74%)
45 (78%)

0.7
0.7
0.7
0.7

the pathogenesis and progression of a variety of
cancers.33–37 Our rules imply that gene MONAP is
up-regulated in colon tumor samples. It is
consistent with the established notion. Moreover,
just as Desmin, MONAP is also identiÞed as one
of three known hub cancer genes in colon cancerspeciÞc gene network.28 hnRNP belongs to the
subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins which are associated with pre-mRNAs in the nucleus and appear
to influence pre-mRNA processing and other
aspects of mRNA metabolism and transport. Thus
its dysregulation may cause the occurrence of
cancers. Hevin encodes the protein which is
implicated in tumor cell growth, differentiation
and metastasis, and may play the role of tumorsuppressor.38–44 Our rules show that if Hevin is
down-regulated in the colon tissue samples, then
the samples are more likely from the colon tumor
patients. It rightly defends the argument that Hevin
is the repressor of tumors. EF1R is associated with
several functions including translation elongation,
actin Þlament depolymerization, apoptosis, and
ubiquitin-mediated protein degradation, etc. Its
role in oncogenesis has been investigated by some
researchers.45–49 Calgizzarin encodes the protein
which belongs to the group of S100 proteins
involved in the Ca 2+ signaling network, and
regulates intracellular activities such as cell growth
and motility, cell cycle progression, transcription,
and cell differentiation50,51 Chromosomal rearrangements and altered expression of this gene
have been implicated in tumor metastasis. In,52
calgizzarin is characterized as a proteomic marker
of colorectal cancer due to its significant upregulation in colorectal carcinoma. The same
observation is provided in.53–55 Tanaka et al detect
Cancer Informatics 2009:7
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Table 8. 20 gene pairs with high prediction accuracy in the DLBCL dataset.
1st – 2nd Probe ID

Correctly-classiÞed sample
number (accuracy)

α

AFFX-BioC-3_at–M95925_at

46 (79%)

0.8

AFFX-BioC-3_at–U70663_at

48 (83%)

0.8

AFFX-M27830_5_at – X70811_at

49 (84%)

0.8

AFFX-M27830_5_at – U46744_at

49 (84%)

0.8

AC002450_at–M95925_at

47 (81%)

0.8

AC002450_at–U48213_at

47 (81%)

0.8

AC002450_at–HG4020-HT4290_s_at

48 (83%)

0.8

M95925_at–X70811_at

46 (79%)

0.8

U23028_at–U70663_at

47 (81%)

0.8

U23028_at–X70811_at

48 (83%)

0.8

U51903_at–U70663_at

48 (83%)

0.8

U51903_at–X70811_at

47 (81%)

0.8

U66702_at–U70663_at

47 (81%)

0.8

U66702_at–HG4020-HT4290_s_at

48 (83%)

0.8

U66702_at–U90543_at

52 (90%)

0.8

U70663_at–U83908_at

47 (81%)

0.8

U70663_at–X83412_at

46 (79%)

0.8

U70663_at–X77777_s_at

47 (81%)

0.8

U70663_at–X16660_cds1_s_at

46 (79%)

0.8

U70663_at–U46744_at

47 (81%)

0.8

that the expression of human calgizzarin is
remarkably elevated in colorectal cancers compared
with that in normal colorectal mucosa by a large
scale random cDNA sequencing and Northern blot
analysis.56 Our rules express the same tendency
that calgizzarin is over-expressed in colon tumors.
Likewise, our rules demonstrate that TPM1 is
down-regulated in colon tumor that coincides with
the Þnding reported in.57 Our rules exhibit that
PCBD1 is up-regulated in colon tumor, but very
few literatures reports the same result. Additionally, there are several genes tightly associated with
colon tumor among the marked gene pairs. In our
rules, if MIF (macrophage migration inhibitory
factor) is up-regulated, then the sample tends to
come from tumor tissue. A number of investigations have demonstrated that MIF promotes colon
tumor and the other cancers.58–63 Thus, our rules
conform to the documented evidence. CDH3 has
been found to be involved in a broad spectrum of
cancers including colorectal cancer.64–71 The gene
is identiÞed as accurate prognostic indicator of
several tumors due to its marked up-regulation in
Cancer Informatics 2009:7

these tumors.66,68,71,72 Our rules show that it is
over-expressed in colon tumor as well.
In summary, the majority of important genes
relevant to the pathogenesis of colon tumor are
marked by our method. The other identified
up-regulated genes include Hsp60, Human serine
kinase mRNA, IPL1, HYPOTHETICAL PROTEIN
IN TRPE 3’REGION and COL11A2 while downregulated genes encompass MYL9, ACTIN,
MaxiK, MGP, GLUT4, MYOSIN HEAVY CHAIN
and HCC-1. Some of them have deÞnite biological
meaning while the others remain to be explored.
Here what we want to emphasize is that the genes
distinguishing tumor from normal tissues well
involve not only muscle-speciÞc ones but also
non-muscle-speciÞc portion. This is in agreement
with the Þnding reported in.22 It also reßects the
complexity of cancerous pathogenesis.

Lung cancer dataset
In this dataset, we identify eight genes with
comparatively strong prediction power individually.
129
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Table 9. Comparison of best prediction accuracy for the CNS tumor dataset.
Methods
(feature selection + classiÞcation)b

# Selected
genes
1
2
8
1–200
150
1–200
1
1–200
1–200
1–200
20
29
74c
74c
74c

α depended degree + decision rules
[this work]
Signal to noise ratios + k-NNs19
Signal to noise ratios + Weighted voting19
Signal to noise ratios + SVMs19
Signal to noise ratios + SPLASH19
Signal to noise ratios + TrkC19
Signal to noise ratios + Staging19
Signal to noise ratios + staging, k-NNs and TrkC19
Signal to noise ratios + SVM, k-NNs and TrkC19
HFW + C4.520
HFW + NaiveBayes20
Discretization + Single C4.512
Discretization + Bagging C4.512
Discretization + AdaBoost C4.512

# Correctly-classiÞed
samples (accuracy)
50 (83%)
54 (90%)
47 (78%)
46 (77%)
45 (75%)
45 (75%)
40 (67%)
41 (68%)
48 (80%)
48 (80%)
45 (75%)
52 (86.67%)
51 (85%)d
53 (88%)d
53 (88%)d

b
The methods include two sections: feature selection methods and classiÞcation methods. The decision trees classiÞcation methods are
also involved in feature selection.
c
74 is the number of the genes withheld for the actual learning process instead of the number of the genes contained in the decision trees,
which is not provided in.12
d
Tenfold cross-validation accuracy is provided.

Our rules reveal that the reduced expression of each
gene is correlated with the poor prognosis of the
cancer. Owing to Þve out of the eight genes have
no annotation available in raw dataset, we only
learn about the other three genes: TCEAL1,
GEMIN5 and TMPO. TCEAL1, also named as p21,
which belongs to the Cip/Kip family of cyclin

dependent kinases, has been identiÞed as a gene
whose product is tightly associated with development and metastasis of several cancers.73–77 Direct
and indirect evidence has proved that a decrease in
the expression levels of the gene might enhance
tumor formation, progression and bad prognosis.
GEMIN5 encodes the protein which is part of a

Table 10. Comparison of best prediction accuracy for the colon tumor dataset.
Methods
(feature selection + classiÞcation)

# Selected
genes

# Correctly-classiÞed
samples (accuracy)

α depended degree + decision rules

1

52 (84%)

[this work]

2

56 (90%)

3

57 (92%)

50

52 (84%)

6

49 (79%)

6

51 (82%)

6

56 (90%)

9

58 (94%)

4

58 (94%)

4

53 (85%)

26

55 (89%)

107

HykGene + k-NNs, SVMs, C4.5, NB
MAVE + logistic discrimination

108

Clustering and rough sets attribute reduction + k-NNs

109

109

Clustering and rough sets attribute reduction + NB

Clustering and rough sets attribute reduction + C5.0
110

MRMR + NB
RBF + C4.5

111

ReliefF + C4.5

111

CFS-SF + C4.5111

130

109
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Table 11. Comparison of best prediction accuracy for the lung cancer dataset.
Methods
(feature selection + classiÞcation)

# Selected
genes

# Correctly-classiÞed
samples (accuracy)

α depended degree + decision rules

1

33 (85%)

[this work]
HFW + C4.5

20

HFW + NaiveBayes20
FCBF + C4.5

20

FCBF + NaiveBayes
CFS-SF + C4.5

20

20

CFS-SF + NaiveBayes
ReliefF + C4.5

20

20

ReliefF + NaiveBayes

20

large macromolecular complex localized to both
the cytoplasm and the nucleus that plays a role in
the cytoplasmic assembly of small nuclear
ribonucleoproteins (snRNPs). In,78 Lee et al suggest
that Gemin5 overexpression inhibts tumor cell
motility so as to may play a role of suppressing
metastatic progression. This conforms to our rules.
We have not found any evidence indicating that the
expression levels of TMPO were correlated with
prognosis of cancers. But there are investigations
showing that the gene is deregulated in various
human tumors.79,80
In addition, we marked eight gene pairs with
good prediction performance. Apart from the

2

32 (82%)

12

35 (90%)

18

35 (90%)

12

31 (79%)

12

24 (62%)

13

26 (67%)

13

24 (62%)

12

24 (62%)

18

25 (64%)

non-annotated genes, the involved genes
encompass SMAC, PFDN2, FLJ10829, LOC51646,
FLJ10326, FLJ12438, GYS10.145 and MSH5.
Our rules imply that the decreased expression of
these genes indicate a poor prognosis of NSCLC
patients- relapse or metastasis. SMAC encodes an
inhibitor of apoptosis protein (IAP)-binding
protein. A wide variety of investigations have
revealed the low expression levels of SMAC
correlate with a worse prognosis in many tumor
types including NSCLC.81–92 At the same time,
some researchers propose the idea of treating
cancers by enhancing SMAC expression in tumor
cells.83,85–87,89 MSH5 encodes a member of the

Table 12. Comparison of best prediction accuracy for the DLBCL dataset.
Methods
(feature selection + classiÞcation)

# Selected
genes

# Correctly-classiÞed
samples (accuracy)

α depended degree + decision rules

1

48 (78%)

[this work]

2

52 (90%)

13

44 (76%)

Signal to noise ratios + Weighted voting
Signal to noise ratios + k-NNs

24

9
24

Gradient descent algorithm + SVMs
HFW + C4.5

20

HFW + NaiveBayes
FCBF + C4.5

20

20

FCBF + NaiveBayes
ReliefF + C4.5

20

20

ReliefF + NaiveBayes
e

20

24

unknown

41 (71%)
e

45 (78%)

22

44 (76%)

19

50 (86%)

27

27 (47%)

27

31 (53%)

22

25 (43%)

19

31 (53%)

No related data is provided.
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mutS family of proteins that are involved in DNA
mismatch repair or meiotic recombination (MMR)
processes. It is a strong candidate for lung cancer
susceptibility as deÞciency of MMR has been
documented to have a role in lung cancer.93 Hence,
it is quite possible that the downregulation of the
gene results to unfavorable clinical outcome of
tumors.

DLBCL dataset
In this dataset, we marked four genes with relatively
excellent prediction ability individually. The four
genes are EZF, IGF2, CEBPE and BTF1. Our rules
indicate that elevated expression of EZF, CEBPE
or BTF1 may cause a worse prognosis of DLBCL
while abundant expression of IGF2 implies a better
prognosis. In,93 IGF2 is also identiÞed as a positive
indicator of DLBCL prognosis. Whereas previous investigation indicates that these genes are
involved in cancerous pathogenesis, further
biological insights remain to be clariÞed.
Some genes lying in the gene pairs we selected
in the dataset maybe have important biological
relevance. DBP is responsible for high, tissuespeciÞc expression of albumin in fully differentiated hepatocytes, which is expressed by adult not
fetal liver cells, and is quickly down-regulated in
proliferating hepatocytes.94 Our rules indicate that
if the gene is down-regulated in one DLBCL
patient, then the patient is inclined to have a favorable prognosis. That sounds reasonable. TGM2
encodes the protein which is the enzyme that catalyzes the crosslinking of proteins and appears to
be involved in apoptosis. Oudejans et al point out
that differences in apoptosis resistance occurring
between DLBCL samples link up with distinct
clinical outcome.95 Since the abundant expression
of TGM2 activates the induction of the apoptosis,
the upregulation of the gene might mean an
excellent prognosis. Our rules reßect the tendency.
In addition, in,96 Mishra et al suggest that TGM2
modiÞcation of p53 oncoprotein could be an additional mechanism whereby TGM2 could facilitate
apoptosis. In,97 Mangala et al hold that TGM2induced alterations in the extracellular matrix could
effectively inhibit the process of metastasis. In,98
Xu et al argue that TGM2 acts as an inhibitor of
tumor progression in combination with another
gene. PDCD4 encodes a protein localized to the
nucleus in proliferating cells which is thought to
play a role in apoptosis but the speciÞc role has not
132

yet been determined. Our rules imply that decreased
expression of the gene is associated with a good
prognosis. It appears to contradict with some previous reports,99–103 whereas Lankat-Buttgereit et al
point out that the function of Pdcd4 might be cell
type speciÞc and a role for Pdcd4 in apoptosis or
as a tumor suppressor might be limited to certain
cell types. 104 The other identified genes like
HRES-1, DTNA,VIPR1, BTF1, HAB1, PTPRN2,
EIF2B, IQGAP2 etc., overall possess strong class
discriminative power, while their biological
mechanism indicating the clinical outcome of
DLBCL or other tumors remain unclear.

Conclusion
Using gene expression patterns to conduct
classiÞcation or prediction of cancer is often faced
with the dilemma: genes (features) far outnumber
samples (instances), which will bring about weak
prediction efÞciency or effect if the model is not
chosen reasonably. Another concern is the interpretability of the prediction model when biologists
and clinician care for your investigation. Here we
employ feature selection to overcome the Þrst difÞculty and decision rules to handle the second
trouble. We propose one way of feature selection
on the basis of the depended degree, a concept from
rough set theory. As the canonical deÞnition of the
depended degree is too stringent to perform feature
selection well, we extend its deÞnition under soft
computing consideration. We deÞne the concept
of α depended degree, whereby we are capable of
screening highly discriminative features. Additionally, our work is in accordance with the principle
of Occam’s razor: when deciding among many
models which make equivalent predictions, choose
the simplest one. For this purpose, we only use
single genes or gene pairs to build decision rules,
which are used to execute prediction of cancer.
Results demonstrate that our models work well in
that the picked single genes and gene pairs overall
give rise to excellent prediction, and meanwhile
some biologically signiÞcant genes are identiÞed.
In general, our method is simpler and more interpretable than most of previously proposed
approaches, since our model is based on rules and
our rules are created via very few genes. Moreover,
our model is robust as we are able to tune our
parameters to meet different datasets. Indeed,
through comparison, we discover our method outperforms or at least match other algorithms in
Cancer Informatics 2009:7
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simplicity and efÞcacy. It is not strange at all that
one or two-gene models are able to result in
accurate cancerous prediction because the single
genes or gene pairs possibly are the biological or
clinical indicators of some speciÞc cancer or general cancer. It appears that one or two gene prediction models are overly simple in that the routine
belief is that cancerous pathogenesis is involved
in complex systems composed of multi-genes.
Whereas our models do not violate the habitual
notion in that we have various genes or gene pairs
which can cause accurate prediction individually
so as to be regarded as candidate markers of cancer.
In contrast, some prediction models are not applicable for they contain too many parameters (genes)
so that overÞtting happens easily. Similar idea is
expressed in4,7,13,15,105 as well. Another advantage
of our models is that signiÞcant biomarkers can be
identiÞed with ease thanks to the operation of few
genes once while it is hard to assess which gene is
more important by multi-gene models for they run
on the basis of a group of genes.
We test our method on several gene expression
datasets including CNS tumor, colon tumor, lung
cancer and DLBCL. In each dataset, we identify
several important genes with documented biological relevance to the malignancy or the cell type.
In the CNS tumor dataset, some signiÞcant genes
like GPS2, beta-NAP, KIAA0220 gene, NSCL1
etc., are identiÞed. In the colon tumor dataset, we
succeed in choosing the genes highly related to
colon tumor or other tumors. They include Desmin,
CRP, MONAP, hnRNP, Hevin, EF1R, calgizzarin,
TPM1, PCBD1, MIF etc., wherein calgizzarin
has been emphasized as a proteomic marker of
colorectal cancer.52 In the lung dataset, TCEAL1,
GEMIN5, TMPO, SMAC, MSH5 etc. genes associated with the pathogenesis and progression of a
variety of cancers are marked by us. In the DLBCL
dataset, IGF2, DBP, TGM2, PDCD4 etc., are identiÞed. Their close relationship with tumor occurrence, progression, metastasis and relapse has been
widely explored.
Generally speaking, most of the genes associated
with tumors encode the proteins involved in cell
growth, motility and differentiation, apoptosis,
angiogenesis, metabolism, chromosomal rearrangement and translocation, and immune reaction. It is
worth noting that whereas there may exist a few
particular markers for some speciÞc tumor, a majority
of tumor markers might be shared by several
tumors. In addition, it is possible that the repressor
Cancer Informatics 2009:7

of some tumor acts as the promoter of another
tumor. And it is not impossible that the enhancer of
some tumor in one stage transforms into the inhibitor of the same tumor during the other stage.
Another issue concerned with molecular prediction of cancer is whether the prediction performance of one gene or gene set is proportional to
its biological interest. We identify some genes
which own strong prediction power while their
biological or clinical involvements remain unobvious. Whether these genes are indeed correlated to
the pathogenesis of cancer, or merely coincidence?
This is an important problem, deserving further
investigation.
In summary, our method uses very few genes
to build rule classiÞers of cancer. These classiÞers
can carry out comparatively accurate prediction.
The efÞcacy of our method has been manifested
to be satisfactory by testing on four gene expression datasets. Our follow-up study is to examine
our method by more microarray data, including
multi-class datasets. In addition, we plan to design
more powerful and robust rule classiÞers in conjunction with other machine learning algorithms.

Methods and Materials
Rough sets
In reality, when we are faced with a heap of data,
we often want to learn about them with already
known knowledge. However, a majority of data
cannot be precisely deÞned by known knowledge.
Thus, in rough set theory, Pawlak describes illdeÞned data by designing two concepts: upper
approximations and lower approximations, based
on the equivalence relation, which is also referred
to as one knowledge on the studied object set.
DeÞnition 1 Let U be a universe of discourse,
X ⊆ U, and R is an equivalence relation on U. U/R
represents the set of the equivalence class of U
induced by R. R * X, R * X, br(R, X), pos(R, X) and
neg(R, X) represent the lower approximation, upper
approximation, boundary region, positive region and
negative region of X on R in U, respectively, where
R * X = ∪ {Y ∈U /R | Y ⊆ X },
R * X = ∪ {Y ∈U /R | Y ∩ X ≠ ∅},
pos ( R, X ) = R * X ,
br ( R, X ) = R * X − R * X ,
neg ( R, X ) = U − R * X .
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If R * X = R * X, then X is called deÞnable or the
precise set on R; otherwise X is called indeÞnable
or the rough set on R.6
The data studied by rough set theory are mainly
organized in the form of decision tables. One decision table can be represented as S = (U , A = C ∪ D ),
where U is the set of samples, C the condition
attribute set and D the decision attribute set. In the
decision table, we deÞne the function Ia that maps
a member (sample) of U to the value of the member on the attribute a (a ∈ A), and an equivalence
relation R(A’) induced by the attribute subset
A’ ⊆ A as: for x, y ∈ U, xR(A’) y if and only if
Ia(x) = Ia(y) for each a ∈ A’.
In,17 Pawlak deÞnes a decision logic language
(DLL) for decision table S = (U , A = C ∪ D ) as:
each (a, v) is an atomic formula, where a ∈ A and
v ∈ Va (set of all the values of a); if ϕ and ψ are
formulas, then so are ¬ϕ, ϕ∧ψ, ϕ∨ψ, ϕ→ψ, and
ϕ↔ψ. The semantics of DLL are deÞned through
the model of decision tables. The satisÞability of
a formula ϕ by an object x in S, denoted by xş Sϕ
or for short xş ϕ if S is understood, is deÞned by
the following conditions:
(1)
(2)
(3)
(4)
(5)
(6)

xş (a, v) if and only if Ia(x) = v,
xş ¬ϕ if and only if not xş ϕ,
xş ϕ∧ψ if and only if xş ϕ and xş ψ,
xş ϕ∨ψ if and only if xş ϕ or xş ψ,
xş ϕ→ψ if and only if xş ¬ϕ∨ψ,
xş ϕ↔ψ if and only if xş ϕ → ψ and xş ψ→ϕ.

We call the set mS(ϕ) = {x ∈ U | xş Sϕ} the
meaning of formula ϕ in decision table S. mS(ϕ)
is simply written as m(ϕ) if S is understood. On
the other hand, we call ϕ a description of object
set m(ϕ). Obviously, the following properties
hold:
(a)
(b)
(c)
(d)
(e)
(f)

m((a, v)) = {x ∈ U | Ia(x) = v},
m(¬ϕ) = ∼m(ϕ),
m(ϕ∧ψ) = m(ϕ) ∩ m(ψ),
m(ϕ∨ψ) = m(ϕ) ∪ m(ψ),
m(ϕ→ψ) = ∼m(ϕ) ∪ m(ψ),
m(ϕ↔ψ) = (m(ϕ) ∩ m(ψ)) ∪ (∼m(ϕ) ∩ ∼m(ψ)).

In rough set theory, the depended degree of an
attribute subset P by an attribute subset Q is
denoted by γ p(Q) and is deÞned as
γ P (Q) =
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|POSP(Q)|
,
|U |

where |POS P (Q )| = | ∪ pos(P, X ) | represents the
size of the union of the positive region of each
equivalence class in U/R(Q) on P in U, and U
represents the size of U (set of samples).
If Q is the decision attribute D, and P a subset
of condition attributes, then γ p(D) indicates the
depended degree of the condition attribute subset
P by the decision attribute D. It means that, to what
degree, P can discriminate the distinct classes of D.
Thus, γ p(D) rightly reßects the classiÞcation power
of the subset P of condition attributes. The greater
γ p (D) is, the stronger classification ability
P inclines to possess.
Rough set theory tries to discover the simplest
decision rules with the equivalent explaining
power and classiÞcation performance as more
complicated rules. One decision rule with the form
of “A ⇒ B” indicates that “if A, then B”, where A
is the description of condition attributes and B the
description of decision attributes. The conÞdence
of a decision rule A ⇒ B is deÞned as:
X ∈U /R (Q )

confidence ( A ⇒ B) =

support ( A ∧ B)
,
support ( A)

where support (A) denotes the proportion of the
samples satisfying A and support (A ∧ B) the proportion of the samples satisfying A and B simultaneously. According to the DLL, the conÞdence of
a decision rule A ⇒ B is rewritten as:
confidence ( A ⇒ B) =

m( A) ∩ m( B)
m( A)

.

The conÞdence of a decision rule implies the
reliable degree of the rule. If one decision rule has 100%
conÞdence, we call it the consistent decision rule.
In the previous studies of classifying cancer by
gene expression proÞles using rough set theory,
the measure of depended degree is often set as the
basis of ranking genes. 9,10 However, as the
canonical deÞnition of depended degree is overly
stringent, sometimes it is not able to rightly express
the discriminatory power of features. Hence, here
we extend the deÞnition of depended degree under
soft computing consideration.
DeÞnition 2 Let U be a universe of discourse,
X ⊆ U, 0 # α # 1 and R is an equivalence relation
on U. pos(R, X, α) representing the α positive
region of X on R in U, is deÞned as:
pos(R, X , α ) = ∪{Y ∈ U /R | | Y ∩ X | / | Y |$ α }.
Cancer Informatics 2009:7
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Correspondingly, the α depended degree of an
attribute subset P by an attribute subset Q, denoted
by γ p(Q, α), is deÞned as:
γ P (Q, α ) =

|POSP (Q, α )|
|U |

where |POS P (Q,α )| = | ∪ pos (P , X , α ) | represents the
size of the union of the α positive region of each
equivalence class in U/R (Q) on P in U.
Obviously, the deÞnition of α depended degree
is a generalization of the deÞnition of depended
degree as when α equals to 1, both deÞnitions are
equivalent. We choose α depended degree instead
of depended degree as the basis of screening
features. Once α value is determined, we only
choose the genes or gene pairs with 1 of γ p(D, α)
value to build classiÞcation (decision) rules. Suppose g is one of the selected genes and U sample
set. U/R(g) = {c1(g), c2(g), …, cn(g)} represents
the set of the equivalence class of samples induced
by R(g). Two samples s1 and s2 belong to the same
equivalence class of U/R(g) if and only if they have
the same value on g. In addition, we represent the
set of the equivalence class of samples induced by
R(D) as U/R(D) = {d1(D), d2(D), …, dm(D)}, where
D is the class (decision) attribute. Two samples s1
and s2 belong to the same equivalence class of U/
R(D) if and only if they have the same value on D.
For each ci(g) (i = 1, 2, …, n), if there exists some
dj(D) ( j ∈ {1, 2,…, m}), satisfying |ci(g) ∩ dj(D)|/
|ci(g)| $ α, then we generate the classiÞcation rule:
A(ci(g)) ⇒ B(dj(D)), where A(ci(g)) is the formula
describing the sample set ci(g) by g value and
B(dj(D)) is the formula describing the sample set
dj(D) by the class value. In the case of gene pairs,
we construct classiÞcation rules through the same
strategy. Here what we want to emphasize is that
only the single genes or gene pairs chosen by all
X ∈ U /R (Q )

the leave-one-out training sets are used for building
classiÞcation rules.
The conÞdences of the rules generated by our
approach depend on α. The following theorem
states the relationship between α and the conÞdences of the induced rules.
Theorem 1 The conÞdence of each induced
decision rule by our way is no less than α.
Proof. For any condition attribute subset P of size
one or two, if γ p(D, α) = 1, then P will be chosen by
our way. Suppose the decision rule A ⇒ B is produced
by P. Then by our way, we have m(A) ∈ U/R(P),
m(B) ∈ U/R(D) and |m(A) ∩ m(B)|/|m(A)| $ α. As
confidence ( A ⇒ B) = m( A) ∩ m( B) / m( A) , the
conclusion is founded.
Therefore, by tuning α value, we can not only
control the size of the set of selected single genes
or gene pairs, but also ensure the conÞdence of
derived decision rules.
For the cancer classiÞcation problem, every
microarray data collected can be represented as a
decision table with the form of Table 13. In the
microarray data decision table, there are m samples
and n genes. Every sample is assigned to one class
label. g(x, y) represents the expression level of gene
y in sample x.

Dataset
CNS tumor dataset
The dataset is about patient outcome prediction for
central nervous system embryonal tumor.19 In this
dataset, there are 60 observations, each of which is
described by the gene expression levels of 7129
genes and a class attribute with two distinct
labels—Class 1 (survivors) versus Class 0 (failures).
Survivors are patients who are alive after treatment
while the failures are those who succumbed to their
disease. Among 60 patient samples, 21 are labeled
as “Class 1” and 39 are labeled as “Class 0”.

Table 13. Microarray data decision table.
Samples

Condition attributes (genes)

Decision attributes (classes)

Gene 1

Gene 2

…

Gene n

Class label

1

g (1, 1)

g (1, 2)

…

g (1, n)

Class (1)

2

g (2, 1)

g (2, 2)

…

g (2, n)

Class (2)

…

…

…

…

…

…

…

…

…

…

…

…

m

g (m, 1)

g (m, 2)

…

g (m, n)

Class (m)
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Table 14. Summary of the four gene expression datasets.
Dataset

# Original genes

Class

# Samples

7129

Class 1/Class 0

60 (21/39)

CNS Tumor
Colon Tumor

2000

negative/positive

62 (40/22)

Lung Cancer

2880

relapse/non-relapse

39 (24/15)

DLBCL

6817

cured/fatal

58 (32/26)

Colon tumor dataset
The dataset contains 62 samples collected from
colon-cancer patients.22 Among them, 40 tumor
biopsies are from tumors (labeled as “negative”)
and 22 normal (labeled as “positive”) biopsies are from healthy parts of the colons of the
same patients. Each sample is described by
2000 genes.
Lung cancer dataset
The dataset contains 39 NSCLC (Non-Small Cell
Lung Cancer) samples, 24 of which are from
patients with metastasis (labeled as “relapse”)
and 15 are from the patients with disease-free
based on both clinical and radiological testing
(labeled as “non-relapse”).23 The total number of
genes is 2880.
DLBCL dataset
The dataset is about patient outcome prediction
for DLBCL.24 The total of 58 DLBCL samples are
from 32 cured patients (labeled as ‘cured’) and
26 refractory patients (labeled as ‘fatal’). The gene
expression proÞle contains 6817 genes.

Table 14 summarizes the four gene expression
datasets.

Data preprocessing
As there exist a few missing attribute values in the
lung cancer dataset, we Þrst Þll each of them with
the mean of all the attribute values from the same
class of samples as the sample containing the missing value.
Because rough set theory is suitable for
handling discrete attributes, we discretize all the
training set decision tables. We utilize the
entropy-based discretization method, proposed
by Fayyad et al.21 This algorithm recursively
applies an entropy minimization heuristic to
discretize the continuous-valued attributes. The
stop of the recursive step for this algorithm
depends on the minimum description length
(MDL) principle. We implement the discretization
in the Weka package.106 Every continuous-valued
attribute is discretized into a one-category, twocategory or three-category attribute. Table 15
shows the discretized decision table for the CNS
tumor with the Þrst sample left out. We execute

Table 15. Discretized CNS tumor decision table with the Þrst sample left out.
Condition attributes (genes)f

Samples

Decision attributes (classes)

Gene 1

…

Gene 11

…

Gene 18

…

Gene 7129

Class label

1

‘All’

…

‘(-inf-187]’

…

‘(−330-inf]’

…

‘All’

Class 1

2

‘All’

…

‘(-inf-187]’

…

‘(−330-inf]’

…

‘All’

Class 1

…

…

…

…

…

…

…

…

…

20

‘All’

…

‘(-inf-187]’

…

‘(−330-inf]’

…

‘All’

Class 1

21

‘All’

…

‘(-inf-187]’

…

‘(−330-inf]’

…

‘All’

Class 0

22

‘All’

…

‘(187-inf]’

…

‘(−330-inf]’

…

‘All’

Class 0

…

…

…

…

…

…

…

…

…

58

‘All’

…

‘(-inf-187]’

…

‘(-inf−330]’

…

‘All’

Class 0

59

‘All’

…

‘(-inf-187]’

…

‘(−330-inf]’

…

‘All’

Class 0

f

‘All’ represents that one gene has the same value in all samples; ‘(-inf-x]’ represents ‘#x’; ‘(x-inf]’ represents ‘.x’.
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our algorithm for the feature selection and
decision rule induction using this kind of tables.

Validation
We employ leave-one-out cross-validation approach.
For the dataset containing n samples, each sample
is left out in turn, and the learning algorithm is
trained on all the remaining n-1 samples. Then the
training result is tested on the left-out sample. The
Þnal estimate is the average of n test results.
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